Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05505292 · ClinicalTrials.gov registry record · Phase 4
Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers
A Phase 4 study, sponsored by State University of New York College of Optometry.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT05505292 is a Phase 4 study that has completed, run by State University of New York College of Optometry. The registered enrollment target is 32 participants.
The verdict
NCT05505292, a Phase 4 study, has completed, sponsored by State University of New York College of Optometry.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a prospective, single site, randomized, double masked, comparator-controlled study designed to evaluate the efficacy of lifitegrast ophthalmic solution 5% in treating the symptoms of dry eye in soft contact lens wearers as compared to control. We hypothesize that there will be a significant improvement in dry eye symptoms in contact lens wearers using lifitegrast as compared to those being treated with control (lifitegrast vehicle).
Interventions
- DRUG Lifitegrast 5% Ophthalmic Solution
- OTHER Lifitegrast Ophthalmic Solution Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-09-22 |
| Est. Completion | 2023-05-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05505292
The ClinicalTrials.gov registry entry for NCT05505292 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York College of Optometry, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lifitegrast 5% Ophthalmic Solution is the first listed.
NCT05505292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05505292 about?
NCT05505292 is a clinical study titled "Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers". This is a prospective, single site, randomized, double masked, comparator-controlled study designed to evaluate the efficacy of lifitegrast ophthalmic solution 5% in treating the symptoms of dry eye in soft contact lens wearers as compared to control. We hypothesize that there will be a significant ...
What is the current status of trial NCT05505292?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2022-09-22. Estimated completion is 2023-05-15.
What interventions are being tested in trial NCT05505292?
The interventions under investigation include: Lifitegrast 5% Ophthalmic Solution (DRUG), Lifitegrast Ophthalmic Solution Vehicle (OTHER).
Who is sponsoring clinical trial NCT05505292?
This trial is sponsored by State University of New York College of Optometry, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.